Xiangxue Pharmaceutical
Xiangxue Pharmaceutical is a Chinese pharmaceutical company headquartered in Guangzhou that manufactures traditional Chinese medicine products, operates GAP-certified herb plantations, and develops TCR-T cell therapies through its XLifeSc subsidiary for oncology indications.
- Company typePublic
- Founded1997
- HeadquartersGuanzhou, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Xiangxue Pharmaceutical does
Xiangxue Pharmaceutical (广州市香雪制药股份有限公司) is a Chinese pharmaceutical company headquartered in Guangzhou, established in its current corporate form in 1997 (with predecessor Luogang Pharmaceutical Factory dating to 1958), and listed on the Shenzhen Stock Exchange ChiNext board (SZ300147). The company operates three principal business segments: traditional Chinese medicine (TCM) products including Chinese patent medicines (e.g., Antiviral Oral Liquid, Banlangen Granules, Juhong Cough series), TCM resources covering GAP-certified medicinal herb plantations and TCM prescription granules, and biopharmaceuticals centered on TCR-T cell therapy through its wholly-owned subsidiary XLifeSc. It also markets health beverages (Lingcha herbal teas), collagen-based supplements, and medical devices including surgical adhesives and neurosurgical fixation systems.
The company's technology base spans proprietary TCM quality control (China's first fingerprint spectrum QC technology applied to Chinese patent medicines, exceeding Chinese Pharmacopoeia standards, plus a 4C quality management system) and cutting-edge biopharmaceutical capabilities through the TAEST (TCR Affinity Enhanced Specific T-cell Therapy) platform, backed by 150+ international patents and making Xiangxue the second company globally pursuing high-affinity TCR-T gene therapy. Lead candidate TAEST16001 is China's first TCR-T product to receive IND approval, currently in confirmatory clinical trials for soft tissue sarcoma and other NY-ESO-1 positive solid tumors with reported Phase I ORR of 41.7% and Phase II best ORR of 50%. The pipeline also includes TAEST1901 (liver/gastric cancer, IND approved 2022) and XLS-103 (NSCLC/pancreatic cancer, IND approved 2025). Additional technology assets include the Smart TCM platform with AI Four Diagnostic Instrument and IoT-enabled prescription dispensing.
Revenue is generated across multiple streams: OTC consumer products sold through retail pharmacy chains; prescription TCM granules and Chinese patent medicines distributed via hospital and clinical channels; export of TCM products to UK, US, and other markets; health beverages and supplements sold through e-commerce and DTC channels; and, prospectively, licensing/royalty income from TCR-T therapies. Customer segments span end consumers for cold/flu and respiratory products, healthcare providers for TCM prescription products, cancer centers for TCR-T clinical trials, and grassroots community clinics for AI-enabled TCM constitution assessment services. The company maintains a vertically integrated supply chain with GAP plantations across 8+ Chinese provinces, R&D centers in Guangzhou, Beijing, Cambridge UK, and Macau, and 60+ wholly-owned subsidiaries supporting operations from herb cultivation through to finished pharmaceutical products.
Xiangxue Pharmaceutical firmographics
Firmographics- Name
- Xiangxue Pharmaceutical
- Legal name
- 广州市香雪制药股份有限公司
- Website
- https://xphcn.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Xiangxue Pharmaceutical is a Chinese pharmaceutical company headquartered in Guangzhou that manufactures traditional Chinese medicine products, operates GAP-certified herb plantations, and develops TCR-T cell therapies through its XLifeSc subsidiary for oncology indications.
- Ownership category
- akta.pro rank
Xiangxue Pharmaceutical industry classification
Industry- Product category
- Traditional Chinese Medicine
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)
Keywords
Where Xiangxue Pharmaceutical is headquartered
LocationHeadquarters
- HQ city
- Guanzhou
- HQ country
- China
- HQ region
- Asia
Offices12 records
Markets served
Xiangxue Pharmaceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- 中成药及配方颗粒: 香雪制药的核心业务板块，包括抗病毒口服液、橘红痰咳液、板蓝根颗粒、夏桑菊颗粒等中成药产品，以及中药配方颗粒的生产和销售
- 中药饮片: 以化橘红为核心的岭南道地中药饮片，包括化橘红、化橘红胎、化橘红丝饮片等，被评为广东省非物质文化遗产
- 大健康产品: 包括上清饮凉茶、湿湿碎凉茶、胶原蛋白肽果蔬纤维固体饮料等健康饮品和保健品，满足大众健康消费需求
- TCR-T细胞治疗产品: 香雪生命科学专注于TCR-T肿瘤免疫治疗产品研发，TAEST16001已进入确证性临床试验，有望成为国内首个上市的TCR-T产品
- 医疗器械: 包括医用创面封闭型、吻合型、EC型、ZT型等医用粘合剂产品
- 中药资源供应: 在全国多地建立GAP种植基地和GMP生产基地，构建覆盖中药资源开发、精深加工的产业链
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Xiangxue Pharmaceutical product offering
Product offeringCore offering
Xiangxue Pharmaceutical develops, manufactures, and sells Chinese patent medicines, traditional Chinese medicine (TCM) raw materials and formula granules, and biopharmaceutical products, with a strategic research focus on TCR-T cell therapy. Its products serve both medical institutions (prescription and clinical trial supply) and retail/consumer channels (OTC medicines, health beverages, and herbal tea), with manufacturing and QC operations in Guangzhou and supporting subsidiaries across Guangdong, Sichuan, Yunnan, and other provinces.
Product overview
Xiangxue Pharmaceutical operates as a diversified traditional Chinese medicine (TCM) and biopharmaceutical company with three main business segments: 1) Pharmaceutical products including Chinese patent medicines (中成药) such as Antiviral Oral Liquid, Juhong Cough series, Banlangen Granules, and other TCM formulations; 2) Traditional Chinese Medicine resources including medicinal herbs, herbal slices, and GAP-certified raw materials from Huazhou Citri Grandis and other geo-authentic sources; 3) Biopharmaceuticals focused on TCR-T cell therapy products developed by subsidiary XLifeSc. The company also offers health beverages (上清饮凉茶, 湿湿碎凉茶), health supplements (胶原蛋白肽饮料 series), and medical devices (surgical adhesives, brain fixation systems). Digital capabilities include the 香雪智慧中医 platform integrating AI-powered four-diagnostic instruments for TCM constitution assessment and community health services.
Differentiator
Problem solved
Functional benefit
Brands
- 香雪生命科学 (XLifeSc): TCR-T细胞免疫治疗产品和技术的研发企业，国内TCR-T细胞免疫治疗的头部企业
- 香雪智慧中医
- 广东省凉茶博物馆
- TAEST
- 香雪抗病毒口服液
Products and services
- Chinese Patent Medicines (中成药) Branded and generic Chinese patent medicines (oral liquids, capsules, granules, etc.) developed in-house and sold through hospital pharmacy channels and retail pharmacy chains; the company's longest-standing commercial offering.
- TCM Resources — Raw Materials and Formula Granules (中药资源 / 配方颗粒) Standardized TCM herbal raw materials and formula granules produced under fingerprint quality control, supplied to the company's own manufacturing lines, to hospital centralized decoction rooms, and to other pharmaceutical manufacturers.
- XLifeSc TCR-T Cell Therapy Pipeline (香雪生命科学 TCR-T 细胞疗法) Investigational TCR-T cell therapy products for solid tumors, developed and advanced toward clinical trials by the Xiangxue Life Science subsidiary; aimed at hospital oncology departments and clinical trial sites.
- Xiangxue Herbal Health Beverages (香雪凉茶等大健康产品) Branded herbal health beverages and packaged TCM-derived drinks sold through self-operated e-commerce stores, distributor channels, and direct-to-consumer lifestyle events as part of the company's "big health" consumer line.
Quantifiable outcome
- TAEST16001 I期临床试验客观缓解率(ORR)达到41.7%，疾病控制率83.3%
- +3 more outcomes
Companies that use Xiangxue Pharmaceutical
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles3 records
Xiangxue Pharmaceutical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Xiangxue Pharmaceutical partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- 北京大学肿瘤医院core北京大学肿瘤医院作为TAEST16001 II期临床试验的参与中心，共同推进TCR-T细胞治疗的临床研究。
- Athenex Inc.core香雪制药与Athenex扩大战略合作，获得口服紫杉醇、口服伊立替康和Tirbanibulin软膏在中国开发和商业化的独家权利，交易总金额可能达到2亿美元（不含特许权使用费）。此次合作拓展了香雪的新药产品线，包括两个积极的III期临床试验产品和一个准备进入II期的概念验证数据产品。
- 澳门大学core香雪与澳门大学合作建设大湾区中医药国际创新平台及智慧中医产业化示范基地，在澳门及广州建立智慧中医平台及中医社区服务网络，为大湾区提供优质中医药服务。
- GE医疗core香雪与GE医疗正式启动建设细胞治疗产业化区域制备平台和临床转化中心的项目，提升细胞治疗产品的产业化能力。
- 中山大学肿瘤防治中心core中山大学肿瘤防治中心作为TAEST16001 TCR-T细胞治疗I期和II期临床试验的牵头研究中心，与香雪生命科学开展深度临床研究合作。
- Athenex/Axis Therapeuticscore香雪生命科学授权Athenex/ Axis Therapeutics在除中国大陆以外的地区研发、商业化TAEST16001 TCR-T疗法。Axis Therapeutics的TCR-T细胞疗法IND获得美国FDA批准进入临床试验。
- 南方医科大学南方医院minor香雪与南方医科大学南方医院合作建立精准医学中心，推动精准医疗技术的临床应用。
- 中国科学院广州生物医药与健康研究院(GIBH)core香雪与中国科学院（GIBH）合建粤港澳干细胞中心，推动干细胞和再生医学研究。
- 杜德生物minor香雪与杜德生物合作启动全球细胞银行项目，成为国内唯一一家拥有国家级批文和授权资质承接国家组织工程种子细胞库的单位的合作。
- 苏州圣诺生物医药/美国Sirnaomicscore香雪与苏州圣诺生物医药、美国Sirnaomics合作新药创制项目STP705，该项目获得CFDA临床批件，成为中国首个小核酸药物。
- 英国Phynovaminor香雪与英国Phynova合作开发植物药，治疗关节痛及感冒的药品于2015年、2017年先后获得英国MHRA注册批准，开创中药产品在英国上市的先河。
Scale indicators9 records
Recent moves7 records
Expansion highlights5 records
Xiangxue Pharmaceutical competitors and assessment
Company assessmentOthers
- Ping An Healthcare and Technology: Adjacent peer operating TCM telemedicine and AI-assisted TCM diagnosis services. Comparable to Xiangxue's Xiangxue Wisdom TCM platform effort to digitize and scale grassroots TCM delivery in China.
- Athenex Inc. Strategic partner of Xiangxue for oncology pipeline development (oral paclitaxel, oral irinotecan, tirbanibulin) and TCR-T licensing ex-China. Provides access to Xiangxue's TCR-T platform and oral chemotherapy assets.
Emerging players
- JW Therapeutics: Chinese cell therapy company (CAR-T focused, with TCR pipeline) that pioneered the first CAR-T approval in China. Competes directly with Xiangxue's TCR-T platform in the engineered T-cell therapy space with greater clinical experience.
- Carsgen Therapeutics: Chinese cell therapy company focused on CAR-T for solid tumors and hematologic malignancies. Competes with Xiangxue's TAEST platform in solid tumor cell therapy with similar targets (Claudin18.2, GPC3) and broader pipeline.
Regional players
- Guangzhou Baiyunshan Pharmaceutical Holdings: Largest Guangdong-based pharma conglomerate with extensive TCM portfolio (including established cough/cold brands), strong distribution networks, and substantial R&D. Direct regional competitor in Guangdong and major national TCM markets.
Broad incumbents
- Beijing Tongrentang Group: Most prestigious Chinese TCM brand with royal heritage, focused on premium TCM finished products and clinic services. Competes in the same branded Chinese patent medicine category with broader geographic and brand reach.
- Yunnan Baiyao Group: Largest Chinese TCM conglomerate with diversified portfolio including proprietary products, Chinese medicine resources, and pharma distribution. Direct competitor in branded TCM consumer market and overlapping TCM resource supply chain.
Direct peers
- Adaptimmune Therapeutics: Global leader in TCR-T cell therapy with SPEAR T-cell platform, partnered with Athenex/Axis Therapeutics on TAEST16001 ex-China development. Closest international peer in the TCR-T mechanism Xiangxue is pursuing.
- CR Sanjiu Medical & Pharmaceutical: State-backed TCM specialist under China Resources with overlapping product categories in cold/flu treatments, cough remedies, and TCM finished formulations. Direct competitor in OTC retail channels and hospital prescription TCM market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Xiangxue Pharmaceutical social profiles
Digital presenceXiangxue Pharmaceutical compliance and trust
Trust signalCompliance11 records
Xiangxue Pharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xiangxue Pharmaceutical leadership team
Management profileNumber of profiles
Profiles1 record
Xiangxue Pharmaceutical subsidiaries and ownership
Company hierarchySubsidiaries10 records
Xiangxue Pharmaceutical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xiangxue Pharmaceutical M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xiangxue Pharmaceutical
What does Xiangxue Pharmaceutical do?
Xiangxue Pharmaceutical develops, manufactures, and sells Chinese patent medicines, traditional Chinese medicine (TCM) raw materials and formula granules, and biopharmaceutical products, with a strategic research focus on TCR-T cell therapy. Its products serve both medical institutions (prescription and clinical trial supply) and retail/consumer channels (OTC medicines, health beverages, and herbal tea), with manufacturing and QC operations in Guangzhou and supporting subsidiaries across Guangdong, Sichuan, Yunnan, and other provinces.
Is Xiangxue Pharmaceutical a public or private company?
Xiangxue Pharmaceutical is a public company. It is classified as public and is currently operating.
When was Xiangxue Pharmaceutical founded?
Xiangxue Pharmaceutical was founded in 1997. It employs 1,001 to 5,000 people.
Where is Xiangxue Pharmaceutical based?
Xiangxue Pharmaceutical is headquartered in Guanzhou, China, in the Asia region.
How does Xiangxue Pharmaceutical make money?
Six revenue lines are on record. 中成药及配方颗粒 is the primary driver. The others are 中药饮片, 大健康产品, TCR-T细胞治疗产品, 医疗器械 and 中药资源供应.
Who are Xiangxue Pharmaceutical's main competitors?
Others on record are Ping An Healthcare and Technology and Athenex Inc.. Emerging players are JW Therapeutics and Carsgen Therapeutics. Guangzhou Baiyunshan Pharmaceutical Holdings is listed as a regional player. Broad incumbents are Beijing Tongrentang Group and Yunnan Baiyao Group. Direct peers are Adaptimmune Therapeutics and CR Sanjiu Medical & Pharmaceutical.
Does Xiangxue Pharmaceutical have an API?
No public API is recorded for Xiangxue Pharmaceutical.
What industry is Xiangxue Pharmaceutical in?
Xiangxue Pharmaceutical's product category is Traditional Chinese Medicine. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.